Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Rebamipide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 2/20 | 0.52 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.48 |
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.98 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.54 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.54 |
| ▸ | ITGAL | P20701 | 6/20 | 0.54 |
| ▸ | F11 | P03951 | 2/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rebamipide SCHEMBL23346201 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL29560992 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL221527 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL21623658 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL5794018 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL9114879 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL27858766 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL28798513 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL26607917 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL26607915 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104418802-B | rebamipide monohydrate crystal form and preparation method thereof | 重庆汇智药物研究院有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-20150087605-A1 | Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2015-03-26 | — | — | US | claimed |
| CN-104418802-A | Rebamipide monohydrate crystal form and preparation method thereof | CHONGQING HUIZHI PHARMACEUTICAL RES INST CO LTD | 2015-03-18 | — | — | CN | claimed |
| EP-2539435-A2 | MODIFIED SUBSTRATES FOR PROTECTION OF PEPTIDE-IMMOBILIZED SURFACES FROM GAMMA RADIATION DEGRADATION | Corning Incorporated (US) | 2013-01-02 | — | — | EP | claimed |
| WO-2011106222-A2 | MODIFIED SUBSTRATES FOR PROTECTION OF PEPTIDE-IMMOBILIZED SURFACES FROM GAMMA RADIATION DEGRADATION | CORNING INCORPORATED (US) | 2011-09-01 | — | — | WO | claimed |
| US-20110207219-A1 | MODIFIED SUBSTRATES FOR PROTECTION OF PEPTIDE-IMMOBILIZED SURFACES FROM GAMMA RADIATION DEGRADATION | CORNING INCORPORATED | 2011-08-25 | — | — | US | claimed |
| US-10144914-B2 | Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation | CORNING INCORPORATED (US) | 2018-12-04 | — | — | US | disclosed |
| CN-104418802-B | rebamipide monohydrate crystal form and preparation method thereof | 重庆汇智药物研究院有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-104418802-B | rebamipide monohydrate crystal form and preparation method thereof | 重庆汇智药物研究院有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-104418802-B | rebamipide monohydrate crystal form and preparation method thereof | 重庆汇智药物研究院有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20150087605-A1 | Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2015-03-26 | — | — | US | disclosed |
| CN-104418802-A | Rebamipide monohydrate crystal form and preparation method thereof | CHONGQING HUIZHI PHARMACEUTICAL RES INST CO LTD | 2015-03-18 | — | — | CN | disclosed |
| CN-104418802-A | Rebamipide monohydrate crystal form and preparation method thereof | CHONGQING HUIZHI PHARMACEUTICAL RES INST CO LTD | 2015-03-18 | — | — | CN | disclosed |
| CN-104418802-A | Rebamipide monohydrate crystal form and preparation method thereof | CHONGQING HUIZHI PHARMACEUTICAL RES INST CO LTD | 2015-03-18 | — | — | CN | disclosed |
| US-20110207219-A1 | MODIFIED SUBSTRATES FOR PROTECTION OF PEPTIDE-IMMOBILIZED SURFACES FROM GAMMA RADIATION DEGRADATION | CORNING INCORPORATED | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087605-A1 | Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules | ANTXR2, AADAC, HAAO | TACR1 2385/4885MEN1 3815/4885UBASH3B 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.